Latest Headlines

Latest Headlines

GlaxoSmithKline scouts for candidates to replace CEO Andrew Witty

GlaxoSmithKline is casting about for a new CEO. Amid shareholder pressure for a breakup or shake-up or both, the company reportedly has asked its headhunting firm to put together a short list of candidates to replace current chief Andrew Witty.

Linchpins of British biopharma throw weight behind campaign to stay in the EU

If the United Kingdom votes to exit the European Union, AstraZeneca CEO Pascal Soriot, GlaxoSmithKline R&D; Chief Patrick Vallance and others predict it will cause disruption, expense and significant regulatory burdens, while also deterring inward investment.

Only a 'mad' GlaxoSmithKline won't follow my advice, Woodford says

That way madness lies. So said King Lear--and now, so says top U.K. investor Neil Woodford. Only in Shakespeare, it's Lear who's going crazy, and Woodford is certain that the madness falls squarely on GlaxoSmithKline CEO Andrew Witty and the company's board.

HPV rates dive following vaccine introduction, national study says

Merck, GlaxoSmithKline and public health officials in the United States have some big new numbers to tout to promote HPV vaccination. On Monday, a group of federal researchers said that since the introduction of Gardasil in 2006, HPV infection rates in teenage girls have fallen by nearly two-thirds.

Mylan joins the Advair-copycat queue, but approval could be a long slog

Generics makers are finally taking aim at GlaxoSmithKline's hard-to-copy respiratory behemoth Advair, and Mylan refuses to be left behind.

Former GSK staffers help Parexel expand genomics offering

CRO giant Parexel has teamed up with recently axed GlaxoSmithKline scientists to grow its business in genomic-based drug development.

GSK plans $73M upgrade to Nashik plant in India

GlaxoSmithKline plans to invest INR500 million ($73 million) in an upgrade of its manufacturing plant in Nashik northeast of the India financial capital Mumbai to build up output of thyroid and dermatology products, the Business Standard reports.

With pricing power waning, time for Big Pharma to become a lean, mean, well-oiled machine

Waiting for the halcyon days when drugmakers could price drugs without pushback to return? Don't, GlaxoSmithKline U.S. pharma president Jack Bailey says. You'd be better off cutting costs instead. As Bailey recently told Bloomberg, those pricing-power days are over--and that means companies better start focusing on how to "do everything faster, better, cheaper."

GSK partners with Belgian neurostim startup in bioelectronic medicine research

GlaxoSmithKline has been quietly working on bioelectronic medicines for years--after having established an R&D; unit dedicated to it in 2012, which was followed by a $50 million venture fund in 2013, and then a $5 million innovation challenge in 2014. Although it hasn't disclosed much about the fruits of its efforts, it has done a new deal to add to them.

U.K. slaps GSK with $54.4M fine for decade-old pay-for-delay deal

The U.K.'s Competition and Markets Authority was only formed in 2014, but it didn't mind reaching back more than a decade for evidence to slap GlaxoSmithKline with a $54.4 million (£37.6 million) fine. In its first pay-for-delay decision, it said the U.K. company thwarted generic competition to its antidepressant drug Seroxat by paying off a handful of generic players.